Lymphoproliferative Responses to Recombinant HIV-1 Envelope Antigens in Neonates and Infants

Borkowsky, William; Wara, Diane; Fenton, Terry; McNamara, James; Kang, Minhee; Mofenson, Lynne; McFarland, Elizabeth; Cunningham, Coleen; Duliege, Anne-Marie; Francis, Donald; Bryson, Yvonne; Burchett, Sandra; Spector, Stephen A.; Frenkel, Lisa M.; Starr, Stuart; Van Dyke, Russell; Jimenez, Eleanor
March 2000
Journal of Infectious Diseases;3/1/2000, Vol. 181 Issue 3, p890
Academic Journal
Studies lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. Estimated incidence of transmission of HIV-1 from an infected mother to her offspring; Homologous antigen responses; Kinetics of responses to homologous antigens.


Related Articles

  • Immunology: Bacteria stand in for HIV.  // Nature Methods;Apr2012, Vol. 9 Issue 4, p325 

    The article offers information on a research related to creation of HIV vaccine by using soil bacteria that contains tetramannose, draw out the production of antibodies that bind HIV.

  • Vaccines Still Elusive, But Trials Now Conclude Humans.  // Guide;Nov2003, Vol. 23 Issue 11, p46 

    Reports that human testing of a vaccine designed to combine the two research approaches to AIDS vaccines has begun at the University of North Carolina. Use of the body's immune system to make antibodies to fight off AIDS; Training of cytoxic T lymphocytes to identify and eliminate infected...

  • Towards an AIDS Vaccine: Unusual Antibody That Targets HIV Described by Scientists at The Scripps Research Institute.  // Ascribe Newswire: Medicine;6/26/2003, p11 

    A group of scientists from The Scripps Research Institute (TSRI) and several other institutions has solved the structure of an antibody that effectively neutralizes HIV, the virus that causes AIDS. The Problem of HIV and Antibodies HIV causes AIDS by binding to, entering and ultimately, killing...

  • HIV vaccine design and the neutralizing antibody problem. Burton, Dennis R.; Desrosiers, Ronald C.; Doms, Robert W.; Koff, Wayne C.; Kwong, Peter D.; .Moore, John P.; Nabel, Gary J.; Sodroski, Joseph; Wilson, Ian A.; Wyatt, Richard T. // Nature Immunology;Mar2004, Vol. 5 Issue 3, p233 

    Describes approaches to overcoming the problem of eliciting neutralizing antibodies (NAB) to HIV. Neutralization of isolates of HIV-1 from different genetic subtypes by reactive human monoclonal antibodies; Role of the V3 loop of gp120 in virus neutralization; Coreceptor sites as NAB target;...

  • What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Campbell, Grant R.; Loret, Erwann P. // Retrovirology;2009, Vol. 6, p1 

    The human immunodeficiency virus type 1 (HIV-1) trans-activator of transcription protein Tat is an important factor in viral pathogenesis. In addition to its function as the key trans-activator of viral transcription, Tat is also secreted by the infected cell and taken up by neighboring cells...

  • The Man Who Could Beat AIDS. Park, Alice // Time;1/25/2010, Vol. 175 Issue 3, p44 

    The article discusses the work of AIDS researcher David Ho. At his research facility in New York City, Ho is pursuing an AIDS vaccine that would not require the body to generate its own antibodies against the AIDS virus. In the 1980s Ho was among the first to notice a pattern of what turned out...

  • Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers Mehendale, Sanjay; Thakar, Madhuri; Sahay, Seema; Kumar, Makesh; Shete, Ashwini; Sathyamurthi, Pattabiraman; Verma, Amita; Kurle, Swarali; Shrotri, Aparna; Gilmour, Jill; Goyal, Rajat; Dally, Len; Sayeed, Eddy; Zachariah, Devika; Ackland, James; Kochhar, Sonali; Cox, Josephine H.; Excler, Jean-Louis; Kumaraswami, Vasanthapuram; Paranjape, Ramesh // PLoS Clinical Trials;Feb2013, Vol. 8 Issue 2, p1 

    Study Design: A randomized, double-blind, placebo controlled phase I trial. Methods: The trial was conducted in 32 HIV-uninfected healthy volunteers to assess the safety and immunogenicity of prime-boost vaccination regimens with either 2 doses of ADVAX, a DNA vaccine containing Chinese...

  • HIV-1 Env-Specific Memory and Germinal Center B Cells in C57BL/6 Mice. Soldemo, Martina; Pedersen, Gabriel K.; Karlsson Hedestam, Gunilla B. // Viruses (1999-4915);Sep2014, Vol. 6 Issue 9, p3400 

    Continued efforts to define the immunogenic properties of the HIV-1 envelope glycoproteins (Env) are needed to elicit effective antibody (Ab) responses by vaccination. HIV-1 is a highly neutralization-resistant virus due to conformational and glycan shielding of conserved Ab determinants on the...

  • Rational Modifications of HIV-1 Envelope Glycoproteins for Immunogen Design. Phogat, S.; Wyatt, R. // Current Pharmaceutical Design;Jan2007, Vol. 13 Issue 2, p213 

    An effective vaccine against the human immunodeficiency virus type 1 (HIV-1) will likely require the elicitation of broadly neutralizing antibodies as well as cellular responses. The HIV exterior envelope glycoprotein trimers, gp120, and the transmembrane glycoprotein, gp41, mediate entry and...

  • Understanding How Broadly Neutralizing Antibodies Evolve. McEnery, Regina // VAX;Jan2011, Vol. 9 Issue 1, p4 

    The article focuses on the ability of broadly neutralizing antibodies to neutralize HIV at low concentrations. It discusses the study conducted by AIDS vaccine researchers in the U.S. on several antibodies which were isolated from the blood of HIV-infected individuals that were able to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics